Cyclin A antibody
Quick Overview for Cyclin A antibody (ABIN6261138)
Target
See all Cyclin A (CCNA2) AntibodiesReactivity
Host
Clonality
Conjugate
Application
- 
    - 
                                            Specificity
- Cyclin A antibody detects endogenous levels of total Cyclin A
- 
                                            Cross-Reactivity
- Human, Mouse (Murine), Rat (Rattus)
- 
                                            Purification
- The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
- 
                                            Immunogen
- A synthesized peptide derived from human Cyclin A
- 
                                            Isotype
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Application Notes
- WB: 1:500~1:3000 IHC: 1:50~1:200 IF/ICC: 1:100~1:500
- 
                                            Restrictions
- For Research Use only
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Concentration
- 1 mg/mL
- 
                                            Buffer
- Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- 
                                            Preservative
- Sodium azide
- 
                                            Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Storage
- -20 °C
- 
                                            Storage Comment
- Store at -20 °C.Stable for 12 months from date of receipt
- 
                                            Expiry Date
- 12 months
 
- 
                                            
- 
    - 
                                            : "The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer."    in: International journal of oncology, Vol. 51, Issue 5, pp. 1497-1507, (2018)         (PubMed).        
 : "Ovostatin 2 knockdown significantly inhibits the growth, migration, and tumorigenicity of cutaneous malignant melanoma cells." in: PLoS ONE, Vol. 13, Issue 4, pp. e0195610, (2018) (PubMed).
 : "CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions." in: Molecular carcinogenesis, Vol. 56, Issue 10, pp. 2245-2257, (2017) (PubMed).
 : "Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase." in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, Vol. 29, Issue 1, pp. 20-4, (2013) (PubMed).
 
 
- 
                                            : "The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer."    in: International journal of oncology, Vol. 51, Issue 5, pp. 1497-1507, (2018)         (PubMed).        
- 
    - Cyclin A (CCNA2) (Cyclin A2 (CCNA2))
- 
                                            Alternative Name
- Cyclin A
- 
                                            Background
- 
                        Description: May be involved in the control of the cell cycle at the G1/S (start) and G2/M (mitosis) transitions. May primarily function in the control of the germline meiotic cell cycle and additionally in the control of mitotic cell cycle in some somatic cells. Gene: CCNA1 
- 
                                            Molecular Weight
- 53kDa
- 
                                            Gene ID
- 8900
- 
                                            UniProt
- P78396, P20248
- 
                                            Pathways
- PI3K-Akt Signaling, Cell Division Cycle, AMPK Signaling, Mitotic G1-G1/S Phases, DNA Replication, M Phase, Synthesis of DNA
 Target
- 
                    
 
                                     
                                     
                                    